430
Participants
Start Date
June 30, 2002
Study Completion Date
October 31, 2005
Docetaxel
Gemcitabine, Docetaxel
Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
Docetaxel
rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
Hanusch KrankenhausHämatologisch-Onkologisches Zentrum, Vienna
SBALO National Oncology Center, Sofia
SBALO National Oncology Center, Sofia
Cancer Center Plovdiv, Plovdiv
2. Med. Abteilung - LKH-Steyr, Steyr
Intere IV Krankenhaus Wels, Wels
Rambam Medical Center, Oncol. Dep, Haifa
FN U sv. Anny, Brno
Nemocnice Ceske Budejovice, Ceske
Charles University Prague, Dep of Oncology, Prague
Tel Aviv Sourasky Medical Center, Div of Oncology, Tel Aviv
"Sheba Medical Center, Dep of Oncology", Tel Litwinsky
American University of Beirut, Medical Center, Beirut
Rizk Hospital, Beirut
Klinika Onkologii CMuJ, Krakow
Nomocnica Sv. Alzbety, Narodny Onkologicky Ustav, Bratislava
FN Hradec Kralove, Hradec Králové
FN Bulovka, Prague
Central European Cooperative Oncology Group
OTHER